BeiGene

NEWS DESK

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

PR News Desk 03/04/2025

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for

NEWS DESK

BeiGene Unveils Proposed Name Change to BeOne Medicines

PR News Desk 17/11/2024

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.  “Cancer, a leading cause of death worldwide,

NEWS DESK

BeiGene Mourns Death of Beloved Board Member Donald Glazer

PR News Desk 03/11/2024

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to share the news that Donald Glazer recently passed away. Don was a Board member and the chair of the nominating and corporate governance committee. Co-founder, Chairman and CEO John V. Oyler issued the following statement: “We are saddened by the […]

NEWS DESK

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

PR News Desk 26/09/2024

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board’s Audit Committee, effective September 27, 2024. “We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth,” said […]

NEWS DESK

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility

News Desk 23/07/2024

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus, which houses state-of-the-art biologics manufacturing capabilities and a clinical research and development center that further bolster the Company’s differentiated model as

NEWS DESK

BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer

News Desk 18/07/2024

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition. “We are thrilled to […]

NEWS DESK

BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership

News Desk 14/06/2024

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene’s goals to expand its presence and directly manage operations in the MENA region. The collaboration between the two companies began in 2020 and included sales,